Compare McKesson Corporation (MCK) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Petróleo Brasileiro SA — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Petróleo Brasileiro SA trades at $18.01 (market cap $114.31B). The key difference: McKesson Corporation and Petróleo Brasileiro SA are close in size by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| MCK | PBR | |
|---|---|---|
Market Cap | $102.58B | $114.31B |
Sector | Health | Technology |
52-Week High | $995.69 | $22.03 |
52-Week Low | $659.01 | $11.54 |
Enterprise Value | $109.12B | $174.73B |
Dividend Yield | 0.43% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
PBR trades at $17.96, down 3.02% today, with bearish technical signals but strong fundamentals. The company reported robust Q2 2026 results with record production of 3.34 million boe/day and net earnings surging 120% year-over-year. Valuation metrics remain attractive with P/E of 4.63 and ROE of 30.77%. Analyst consensus is bullish with 11 buy ratings out of 22 total coverage.
PBR presents a compelling value opportunity with strong profitability and dividend yield, though regulatory uncertainty and oil price volatility pose risks. The company's production growth trajectory and cost-efficient pre-salt assets support long-term upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
